A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.

Toripalimab is a promising anti-PD-1 antibody, which was well tolerated and demonstrated anti-tumor activity in treatment-refractory advanced solitary malignant tumors. Further exploration in various tumors and combination therapies is warranted.